SG11201405099UA - Stable dosage forms of imatinib mesylate - Google Patents

Stable dosage forms of imatinib mesylate

Info

Publication number
SG11201405099UA
SG11201405099UA SG11201405099UA SG11201405099UA SG11201405099UA SG 11201405099U A SG11201405099U A SG 11201405099UA SG 11201405099U A SG11201405099U A SG 11201405099UA SG 11201405099U A SG11201405099U A SG 11201405099UA SG 11201405099U A SG11201405099U A SG 11201405099UA
Authority
SG
Singapore
Prior art keywords
dosage forms
imatinib mesylate
stable dosage
stable
imatinib
Prior art date
Application number
SG11201405099UA
Inventor
Ravi Kochhar
Annavarapu Ramesh
Suneel Kumar Vasireddy
Roshan Lal Sandal
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of SG11201405099UA publication Critical patent/SG11201405099UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/264—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201405099UA 2012-02-21 2013-02-15 Stable dosage forms of imatinib mesylate SG11201405099UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN499DE2012 2012-02-21
IN498DE2012 2012-02-21
PCT/IB2013/051261 WO2013124774A1 (en) 2012-02-21 2013-02-15 Stable dosage forms of imatinib mesylate

Publications (1)

Publication Number Publication Date
SG11201405099UA true SG11201405099UA (en) 2014-10-30

Family

ID=48093035

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405099UA SG11201405099UA (en) 2012-02-21 2013-02-15 Stable dosage forms of imatinib mesylate

Country Status (7)

Country Link
US (1) US20160015708A1 (en)
EP (1) EP2817030A1 (en)
AU (1) AU2013223749A1 (en)
IN (1) IN2014DN07898A (en)
SG (1) SG11201405099UA (en)
WO (1) WO2013124774A1 (en)
ZA (1) ZA201406139B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2803353B1 (en) * 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
WO2019229648A1 (en) * 2018-05-28 2019-12-05 Shivalik Rasayan Limited Oral compositions of imatinib mesylate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
ITMI992711A1 (en) 1999-12-27 2001-06-27 Novartis Ag ORGANIC COMPOUNDS
CA2424470C (en) 2000-10-27 2009-06-09 Novartis Ag Treatment of gastrointestinal stromal tumors
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1720853B2 (en) 2004-02-11 2023-06-28 Natco Pharma Limited Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
EA201100022A1 (en) 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. METHOD OF OBTAINING A COMPOSITION OF NANOPARTICLES MEZILAT IMATINIB
CA2550702A1 (en) 2006-03-24 2007-09-24 Kensuke Egashira Organic compounds
US20090087489A1 (en) 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
CA2789307A1 (en) 2010-03-29 2011-10-06 Hetero Research Foundation Stable pharmaceutical composition of imatinib
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
MX2013001653A (en) * 2010-08-11 2013-05-22 Synthon Bv Pharmaceutical granulate comprising imatinib mesylate

Also Published As

Publication number Publication date
WO2013124774A1 (en) 2013-08-29
AU2013223749A1 (en) 2014-09-11
US20160015708A1 (en) 2016-01-21
ZA201406139B (en) 2015-05-27
EP2817030A1 (en) 2014-12-31
IN2014DN07898A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
HK1212701A1 (en) Formulations of enzalutamide
GB201507167D0 (en) Administration of web page
SG10201802104QA (en) Pharmaceutical composition of s-ketamine hydrochloride
SG10201802106TA (en) Pharmaceutical composition of s-ketamine hydrochloride
IL273076A (en) Solid dosage form
PL2925305T3 (en) Improved pharmaceutical compositions of pimobendan
EP2864361A4 (en) Dosage regime of fusion compounds
ZA201406082B (en) Use of ccr3-inhibitors
EP2917314A4 (en) Composition of oligomerate
EP2906554A4 (en) Solid forms of nilotinib hydrochloride
IL236312A0 (en) Preparation of 18f-fluciclovine
HK1210783A1 (en) Octahydro-cyclopentapyrrolyl antagonists of ccr2 ccr2
EP2892529A4 (en) Uses of (-)-perhexiline
GB201218012D0 (en) Dosage forms
ZA201406139B (en) Stable dosage forms of imatinib mesylate
TWM433525U (en) Structure of calorifier